Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM

Laura Fontana, Micol E. Fiori, Sonia Albini, Loredana Cifaldi, Serena Giovinazzi, Matteo Forloni, Renata Boldrini, Alberto Donfrancesco, Valentina Federici, Patrizio Giacomini, Cesare Peschle, Doriana Fruci

Research output: Contribution to journalArticlepeer-review


We identified a key oncogenic pathway underlying neuroblastoma progression: specifically, MYCN, expressed at elevated level, transactivates the miRNA 17-5p-92 cluster, which inhibits p21 and BIM translocation by interaction with their mRNA 3′ UTRs. Overexpression of miRNA 17-5p-92 cluster in MYCN-not-amplified neuroblastoma cells strongly augments their in vitro and in vivo tumorigenesis. In vitro or in vivo treatment with antagonis 17-5p abolishes the growth of MYCN amplified and therapy resistant neuroblastoma through p21 and BIM upmodulation, leading to cell cycling blockade and activation of apoptosis, respectively. In primary neuroblastoma, the majority of cases show a rise of miR-17-5p level leading to p21 downmodulation, which is particularly severe in patients with MYCN amplification and poor prognosis. Altogether, our studies demonstrate for the first time that antagomir treatment can abolish tumor growth in vivo, specifically in therapy resistant neuroblastoma.

Original languageEnglish
Article numbere2236
JournalPLoS One
Issue number5
Publication statusPublished - May 21 2008

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)


Dive into the research topics of 'Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM'. Together they form a unique fingerprint.

Cite this